MHB088C + MHB039A

MHB088C + MHB039A is an investigational **combination therapy** comprising two novel monoclonal antibody-based agents developed for the treatment of advanced malignant solid tumors. **MHB088C** is a B7-H3-targeted antibody-drug conjugate (ADC), consisting of a humanized anti-B7-H3 monoclonal antibody linked to a highly potent DNA topoisomerase I inhibitor payload (SuperTopoi), which is 5–10 times more potent than DXd. It is designed for selective tumor cell delivery, robust internalization, and cytotoxicity. **MHB039A** is a bispecific antibody that targets both PD-1 (programmed cell death protein 1) and VEGF (vascular endothelial growth factor), designed to block immune checkpoint and angiogenesis pathways simultaneously. The combination is under Phase I/II clinical investigation to assess safety, tolerability, pharmacokinetics, and antitumor activity in advanced solid tumors, including small cell lung cancer and other advanced malignancies[1][2][4][5][6][8].